Provided are keratin BD-4, an encoding nucleic acid molecule thereof, an expression vector, a host cell, and a pharmaceutical composition containing the keratin. The keratin BD-4 can be used for preparing drugs having antipyretic and analgesic, antitussive and expectorant, and antiepileptic effects.

Method of preparing a keratin-based biomaterial is provided. The method comprises a) reacting keratin with a polymer having at least one of an amine and carboxylic functional group in the presence of a carbodiimide cross-linking agent to form a cross-linked keratin-polymer material; and b) freeze drying the cross-linked keratin-polymer material to form the keratin-based bio-material. A keratin-based biomaterial thus prepared is also provided.

Peptides are provided herein, wherein the peptide bearing one or more amino acid sequence differences relative to SEQ ID NO: 1, with the amino acid sequence differences comprising at least one cysteine replacement.

The present invention provides a keratin BD-10, an encoding nucleic acid molecule, an expression vector, a host cell thereof, a preparation method for BD-10, and a pharmaceutical composition containing the keratin BD-10. Also provides the use of the keratin BD-10, nucleic acid molecule, expression vector, host cell or pharmaceutical composition in the preparation of medicament for antipyretic, analgesic, antitussive, expectorant, anticonvulsant, antiepileptic, anti-hypertension, anti-inflammatory, and antiviral.

A keratin hydrolysate including at least 88% by weight of free amino acids relative to the total weight of the amino acids of the hydrolysate and including a content of free tyrosine between 2% and 4% by weight relative to the total weight of the free amino acids of the hydrolysate. Also, a method for preparing the hydrolysate including the following steps: acid hydrolysis, a pH adjustment and a desalination. Also, the use of the hydrolysate for pet food, aquaculture food, and plant biostimulants.

The present disclosure relates to a method of forming a keratin filament network, comprising: (i) dialysing a solubilized keratin solution in a dialysis buffer solution at a pH of about 2.5 to about 5.5 to obtain purified keratin; (ii) mixing the purified keratin with a salt in the acidic buffer solution; and (ill) drying the solution of step (ii) to form the keratin filament network. In one embodiment, he dialysis buffer solution comprises a weak acid, a denaturing agent and a reducing agent. The said method comprises self-assembly of the keratin filament network. The present disclosure also relates to a keratin filament network comprising at least 2 Type I human hair keratins and at least 2 Type II human hair keratins.

The present invention provides a keratin BD-11, an encoding nucleic acid molecule, an expression vector, a host cell, a preparation method thereof, and a pharmaceutical composition containing the keratin. The keratin BD-11 can be used in the preparation of medicamnet for antipyretic, analgesic, antitussive, expectorant, anticonvulsant, antiepileptic, anti-hypertension, anti-inflammatory, and antiviral.

The present invention relates to novel antiviral compounds which are covalently attached to solid, macro surfaces. In another embodiment, the invention relates to novel antiviral compositions including a polymeric material and, embedded therein, an antiviral compound. In other embodiments, the invention relates to making a surface antiviral and making a polymeric material antiviral.

The present disclosure provides immunomodulatory fusion proteins comprising a collagen-binding domain operably linked to an immunomodulatory domain. The disclosure also features compositions and methods of using the same, for example, to treat cancer.

The disclosure provides methods for treating lung cancer (e.g., non-small cell lung cancer) with an anti-PD-L1 antibody in a patient identified using a polynucleotide or polypeptide marker of the disclosure: CXCL9, KRT8, TRIM29, and/or IFNgamma.